Parp-1 Overexpression As an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia Publisher Pubmed

Summary: Research suggests high PARP-1 levels in AML patients link to poorer survival and could be a therapeutic target. How can this advance AML treatment? #AML #CancerResearch

Pashaiefar H^{1, 2, 3} ; Yaghmaie M^{1, 2, 3} ; Tavakkolybazzaz J⁴ ; Ghaffari SH^{1, 2, 3} ; Alimoghaddam K^{1, 2, 3} ; Momeny M^{1, 2, 3} ; Izadi P⁴ ; Izadifard M^{1, 2, 3} ; Kasaeian A^{1, 2, 3} ; Ghavamzadeh A^{1, 2, 3}
Source: Genetic Testing and Molecular Biomarkers Published:2018

Abstract

Aims: Poly (ADP-ribose) polymerase-1 (PARP-1) plays an important role in the repair of damaged DNA and has prognostic significance in a variety of human malignancies. However, little is known about its expression levels and clinical implication in patients with acute myeloid leukemia (AML). Materials and Methods: Quantitative reverse transcription-polymerase chain reaction was done to evaluate PARP-1 expression levels in the bone marrow of 65 patients with non-M3 AML and 54 healthy counterparts. The correlation of PARP-1 expression with clinicopathological features of non-M3 AML patients was also analyzed. Results: Non-M3 AML patients have higher PARP-1 expression than the healthy controls (p < 0.01). Patients with adverse cytogenetic risk have higher PARP-1 expression than other cytogenetic risk groups (p = 0.004). The PARP-1 median expression level divided AML patients into PARP-1 low-expressed and PARP-1 high-expressed groups. High expression levels of PARP-1 were associated with worse overall survival (OS) (p = 0.01) and relapse-free survival (RFS) (p = 0.005). Moreover, multivariate analysis revealed that high PARP-1 expression was an independent risk factor for both OS and RFS. Conclusions: Our results suggest that PARP-1 overexpression may define an important risk factor in non-M3 AML patients and PARP-1 is a potential therapeutic target for AML treatment. © 2018, Mary Ann Liebert, Inc.